Participates in world’s largest conference on hypertension and shares latest knowledge on hypertension and cardiovascular diseases

On September 28, Daewoong Pharmaceuticals disclosed that it held an academic symposium at the ‘26th ISH Seoul 2016’ that took place in COEX, Seoul from September 24 to 29.

This is an international biannual event to share the latest issues and knowledge on hypertension and cardiovascular diseases and to proposition the prospect of hypertension patient management.

For 4 days from September 25, Daewoong Pharmaceuticals explained the outstanding efficacies of Sevikar, a double-drug combination treatment, Sevikar HCT, a triple-drug combination treatment, Olmetec, antihypertensive treatment for managing hypertension for chronic patients, and their vascular protective functions and hypertensive effects.

On September 28, Prof. Dongju Oh from Korea University lectured on ‘antihypertensive effect and protection from cardiovascular diseases’ and said, “Olmesartan medications such as Olmetec, Olostar, Sevikar and Sevikar HCT not only block coupling of angiotensin II receptors but also increase manifestation of ACE2, effectively treating patients with hypertension and cardiovascular diseases.”

A Daewoong Pharmaceuticals personnel said, “At the International Society of Hypertension, we were able to inform people of the cardiovascular protective function of Olmetec, Olostar, Sevikar and Sevikar HCT and well as their antihypertensive effects. From single to triple-drug combination treatments, we will inform the world that only 1 pill is necessary to manage light to moderate hypertension.”

According to UBIST, the total sales of Olmetec, Olostar, Sevikar and Sevikar HCT was 120 billion won in 2015 and reached 60 billion won in the first half of 2016. Daewoong Pharmaceuticals expects over 120 billion won sales in 2016.

*Photo : Daewoong Pharmaceuticals held an academic symposium at the ‘26th ISH Seoul 2016’ that took place in COEX, Seoul from September 24 to 29.